UY35624A - Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington - Google Patents

Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Info

Publication number
UY35624A
UY35624A UY35624A UY35624A UY35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A UY 35624 A UY35624 A UY 35624A
Authority
UY
Uruguay
Prior art keywords
disease
pridopidine
high dose
treat huntington
huntington
Prior art date
Application number
UY35624A
Other languages
English (en)
Spanish (es)
Inventor
Bassan Merav
Esther Lukasiewicz Hagai
Eyal Eli
Anna Kristina Sveinsdotter Teige Wickenberg
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of UY35624A publication Critical patent/UY35624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY35624A 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington UY35624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
UY35624A true UY35624A (es) 2015-01-30

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35624A UY35624A (es) 2013-06-21 2014-06-23 Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington

Country Status (24)

Country Link
US (1) US10322119B2 (enExample)
EP (1) EP3010506B1 (enExample)
JP (1) JP2016523862A (enExample)
KR (1) KR102316933B1 (enExample)
CN (1) CN105592848A (enExample)
AU (1) AU2014281414A1 (enExample)
BR (1) BR112015029918A2 (enExample)
CA (1) CA2913781C (enExample)
CL (1) CL2015003690A1 (enExample)
DK (1) DK3010506T3 (enExample)
EA (1) EA201690069A1 (enExample)
ES (1) ES2879631T3 (enExample)
HK (1) HK1221646A1 (enExample)
HU (1) HUE054783T2 (enExample)
IL (1) IL242804B (enExample)
MX (1) MX384234B (enExample)
PE (2) PE20160195A1 (enExample)
PH (1) PH12015502691A1 (enExample)
PL (1) PL3010506T3 (enExample)
SG (1) SG11201509729YA (enExample)
TW (1) TW201529069A (enExample)
UA (1) UA122999C2 (enExample)
UY (1) UY35624A (enExample)
WO (1) WO2014205229A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
HUE058288T2 (hu) * 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
PL3419622T3 (pl) 2016-02-24 2024-07-08 Prilenia Neurotherapeutics Ltd. Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny
JP6912574B2 (ja) * 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
BR112019003731A2 (pt) * 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP3570940B1 (en) 2017-01-20 2023-12-13 Prilenia Neurotherapeutics Ltd. Pridopidine for use in the treatment of fragile x syndrome
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
JP2022521457A (ja) * 2019-01-31 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ハンチントン病の進行度の評価方法
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
JP7436524B2 (ja) * 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
EP4030993A4 (en) * 2019-09-17 2023-10-25 F. Hoffmann-La Roche AG Improvements in personalized healthcare for patients with movement disorders
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
CA2884260A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
AU2013323131A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
HUE058288T2 (hu) 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
PE20160195A1 (es) 2016-05-14
HK1221646A1 (zh) 2017-06-09
EP3010506A4 (en) 2017-02-08
MX2015017307A (es) 2016-08-03
CA2913781A1 (en) 2014-12-24
US20140378508A1 (en) 2014-12-25
EP3010506A1 (en) 2016-04-27
WO2014205229A8 (en) 2015-04-09
IL242804B (en) 2022-02-01
TW201529069A (zh) 2015-08-01
KR20160055122A (ko) 2016-05-17
PE20170302A1 (es) 2017-03-31
SG11201509729YA (en) 2015-12-30
JP2016523862A (ja) 2016-08-12
EA201690069A1 (ru) 2016-06-30
EP3010506B1 (en) 2021-05-12
UA122999C2 (uk) 2021-02-03
ES2879631T3 (es) 2021-11-22
AU2014281414A1 (en) 2016-01-21
PL3010506T3 (pl) 2021-11-02
BR112015029918A2 (pt) 2017-07-25
CN105592848A (zh) 2016-05-18
KR102316933B1 (ko) 2021-10-26
DK3010506T3 (da) 2021-07-12
CA2913781C (en) 2022-05-10
MX384234B (es) 2025-03-14
PH12015502691A1 (en) 2016-03-14
HUE054783T2 (hu) 2021-09-28
US10322119B2 (en) 2019-06-18
CL2015003690A1 (es) 2016-10-28
WO2014205229A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
ZA202000028B (en) Use of vibegron to treat overactive bladder
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
MX2016007376A (es) Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2022002356A (es) Forma de dosificacion oral solida que comprende naproxeno y vitamina b12.
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria
AR096674A1 (es) Método de tratamiento de un paciente humano que sufre de la enfermedad de huntington
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
AR082645A1 (es) Composiciones y metodos para tratar sindrome mielodisplasico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211206